Insiders · NEUP

Jane Ryan

Director at Neuphoria Therapeutics Inc. (NEUP) since July 2024

Jane Ryan has filed 3 insider reports with the SEC since July 2024, as director at Neuphoria Therapeutics Inc. (NEUP). The latest filing, on January 21, 2026, reports grant or award at Neuphoria Therapeutics Inc. (NEUP).

Filings
3
Companies
1
Bought on market
None
Sold on market
None

Companies where Jane Ryan is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Neuphoria Therapeutics Inc. logo
NEUP
Neuphoria Therapeutics Inc.
Directorsince July 2024$2.35Jan 21, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Jane Ryan with

Other insiders at the same companies

Questions about Jane Ryan

What is Jane Ryan's role at Neuphoria Therapeutics Inc.?
Jane Ryan reports to the SEC as director at Neuphoria Therapeutics Inc. (NEUP), according to the latest filing on January 21, 2026.
Has Jane Ryan bought or sold stock recently?
No open-market purchases or sales by Jane Ryan are on file. The filings report grant or award.
How do I get alerts when Jane Ryan files?
Follow Jane Ryan on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Jane Ryan (SEC CIK 0002028936). Totals count each trade once, skipping amendments whose original is on file, from Jul 8, 2024 on. View on SEC EDGAR · Get this as JSON